Two more for AtCor
Monday, 08 December, 2008
Medical device company AtCor has signed two new supply agreements worth US$1.5 million for its reflected blood pressure measurement system SphygmoCor.
The new agreements cap an excellent six months for the Sydney company, with supply contracts signed in the period worth US$5.7 million.
The device is aimed at both clinical practice and clinical trials to understand drug efficacy and mechanisms of action.
The SphygmoCor system visibly identifies the effects of reflected blood pressure in the central aortic pressure wave, effects which cannot be detected with standard blood pressure monitoring.
Defective sperm doubles pre-eclampsia risk in IVF patients
A high proportion of the father's spermatozoa possessing DNA strand breaks is associated with...
Free meningococcal B vaccines coming to the NT
The Northern Territory Government has confirmed the rollout of a free meningococcal B vaccine...
Mouth bacteria linked to increased head and neck cancer risk
More than a dozen bacterial species that live in people's mouths have been linked to a...
